Preeclampsia Laboratory Testing Market

Preeclampsia Laboratory Testing Market Outlook

Preeclampsia Laboratory Testing Market to Gain Traction from Significantly Unmet Preeclampsia Diagnostics

The Preeclampsia Laboratory Testing Market is valued at USD 1.4 Bn in 2026 and is projected to reach USD 2.3 Bn,  growing at a CAGR of 8% by 2033. Preeclampsia is known to be potential multisystem progressive pregnancy complication characterized by high blood pressure and organ dysfunction mostly kidney and liver amongst various other symptoms. However, these symptoms are not considered as reliable signs of preeclampsia, owing to their overlap with those occurring in many normal pregnancies. This thus complicates the diagnosis of preeclampsia. Screening of preeclampsia plays a significant role, since at present, delivery is the only mode of cure for preeclampsia.  Rising burden of preeclampsia due to lifestyle disorders, coupled with growth in advancements in medical technologies observed over the recent past across the globe are known to increase the probability of preeclampsia in pregnant women. Fairfield Market Research indicates that the global preeclampsia laboratory testing market will rise at healthy pace of 4.6% CAGR during the period of assessment (2022-2027), reaching market value of US$17,386.1 Mn and volume of 1,22,998 (,000) indicating potential number of women undergoing diagnostic tests by the end of 2027.

Preeclampsia Laboratory Testing Market in Developing Countries Eyes Innovative Diagnostic Solutions

Globally, incidence of preeclampsia ranges between 2-10% of pregnancies. The World Health Organization (WHO) estimates the incidence of preeclampsia to be seven times higher in developing countries than in developed ones. Several clinical and biochemical tests are under evaluation for prediction or early detection of preeclampsia, However, none of them present reliable and cost-effective screening for preeclampsia for use in most developing countries. Large population-based studies are missing, and results are to be validated, albeit intensive research underway. Companies are collaborating with research institutes and universities to develop new kits with low costs.

Development of early diagnostic tests for preeclampsia would minimize the maternal and infant mortality. The awareness around preeclampsia is on the rise recently, mostly because of the campaigns from patient advocacy groups, and welfare associations, viz. Preeclampsia Foundation, Accelerated Access Collaborative, amongst others. This remains a strong factor providing lucrative growth opportunity for development of innovative tests in view of significant unmet need for preeclampsia diagnosis across the globe.

Government and academic institutions are collaborating for better diagnostics and treatment for preeclampsia. The researchers at the University of Strathclyde in partnership with King's College London have received an Artificial Intelligence Health and Care award and funding from U.K. Government. Furthermore, rapid emergence of innovative alternatives such as hand-held screening devices would also boost the uptake of diagnostic tests in the preeclampsia laboratory testing market.

Novel Biomarkers Promise Improved Diagnostics for Patients Boosting Uptake in Preeclampsia Laboratory Testing Market

Multiple novel biomarkers are under development to address the high unmet need. Lack of precision in diagnosis leads to over and under diagnosis due to clinical variation. Inclusion of biomarkers has the potential to lead to greater precision and accuracy thus preventing unnecessary preterm births, hospitalization and medical intervention. Novel biomarkers will lead to improved diagnostic assessment of preeclampsia and its severity.

cfRNA hold great promise in non-invasive diagnostics, though there is still a need for more detailed studies to map the signatures of cfRNA in disease pathogenesis and create disease-specific reference databases. The report estimates that the blood tests segment will contribute to ~41% to the global preeclampsia laboratory testing market in 2021.

Developed Countries Hold Lion’s Share in Preeclampsia Laboratory Testing Market, Asia Pacific Follows Suit

The presence of technologically sophisticated diagnostic laboratories along with ready acceptance of importance of preeclampsia screening at an early stage contribute to the dominance of North America and Europe. Europe is expected to witness a highest CAGR of 6.2% during the forecast period 2022-2027 owing to numerous investigational diagnostic tests for preeclampsia in pipeline.

Preeclampsia laboratory testing market research reveals that Asia Pacific has maintained its high-growth potential and will demonstrate the same till the end of forecast year 2027 due large population base of women of reproductive age. Low- and Middle-Income countries are anticipated to record highest growth rates owing to increasing incidences of preeclampsia and thus urgent need for its diagnosis. A study published in the Pregnancy Hypertension journal (October 2019) reveals that the prevalence of preeclampsia in China has risen from 5.79% in 2005 to 9.50% in 2019. In addition, these regions provide lucrative growth prospects due to huge patient population, increase in research activities, rise in government funding for research & development, and surge in the number of biotechnology companies as compared to the developed countries. Despite high prevalence rate, lack of awareness, reliable and cost-effective screening tests hinders the potential market growth in these regions.

Decline in Fertility Rates and Introduction of Intervening Procedures to Hinder the Market Growth in Near Future

Relative lack of awareness and inadequacy of reliable and cost-effective screening tests for preeclampsia, especially in developing economies, continue to hinder the growth of preeclampsia laboratory testing market. Thus, certain lifestyle and therapeutic interventions are under evaluation which are known to lower the risk of developing preeclampsia. This might impede the market growth. Some of them include low aspirin dose and calcium supplements along with certain lifestyle changes. Significant drop-in fertility rates across the globe would lower the demand for f preeclampsia diagnostic tests and pose a challenge to the market growth.

Key Market Players Prioritizing R&D and Collaborative Activities to Strengthen Market Positioning

Market players holding substantial share in the global preeclampsia laboratory testing market include 

• DiabetOmics
• DRG Instruments GmbH
• Hoffmann-La Roche Ltd.
• GestVision, Inc.
• Lifeassay Diagnostics (Pty) Ltd.
• Metabolomic Diagnostics
• Perkin Elmer, Inc.
• Progenity, Inc.
• Quidel Corporation
• Siemens Healthineers
• Thermo Fisher Scientific, Inc.

The Global Preeclampsia Laboratory Testing Market is Segmented as Below:

By Test Type

• Urine Tests
• Blood Tests

By Preeclampsia Type

• Mild Preeclampsia
• Severe Preeclampsia

By End User

• Hospitals and Clinics
• Diagnostic Centres
• Others

By Geographic Coverage

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa